金山科研平台，产品价格货期咨询微信：jinshanbio Source:E. coli-derived, Contains an N-terminal Met and 6-His tag Accession #:P49427 Purity:>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain. Predicted Molecular Mass:28 kDa Activity:Recombinant Human His6-UbcH3/Cdc34 is a member of the Ubiquitin-conjugating (E2) enzyme family that receives Ubiquitin from a Ubiquitin-activating (E1) enzyme and subsequently interacts with a Ubiquitin ligase (E3) to conjugate Ubiquitin to substrate proteins. Reaction conditions will need to be optimized for each specific application. We recommend an initial Recombinant Human His6-UbcH3/Cdc34 concentration of 0.1-1 µM. Formulation:Supplied as a solution in HEPES, NaCl, DTT and Glycerol.See Certificate of Analysis for details. Molecule Information: UbcH3 Aliases: Cdc34; UBC3; UBE2R1 Entrez Gene IDs: 997 (Human); 216150 (Mouse) Background: UbcH3 Ubiquitin-conjugating Enzyme H3 (UbcH3), also known as Cell Division Cycle 34 (Cdc34), is a member of the Ubiquitin-conjugating (E2) enzyme family. UbcH3 has a predicted molecular weight of 26 kDa. The human protein shares 98% amino acid (aa) sequence identity with the mouse and rat orthologs. In addition to an E2 catalytic core domain, UbcH3 has two Ubiquitin binding sites, UBS1, from aa 205-215, and UBS2, from aa 216-225, and a C-terminal acidic tail domain. UbcH3 is required for efficient cell cycle progression in human cells. UbcH3 interacts with the SCF(Fbw7) and SCF(Skp2) Ubiquitin ligases (E3s) to target the key cell cycle proteins Myc and p27/Kip1, respectively, for ubiquitination and degradation. Furthermore, CK2 has been shown to phosphorylate human UbcH3 on Ser203, Ser222, and Ser231 in cycling cells. The proliferation of cancer cell lines is inhibited following treatment with a human UbcH3 inhibitor, suggesting that UbcH3 also plays a significant role in cancer.